Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Chemotherapy in Treating Patients With Sarcoma of the Uterus

Study:

Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients who have advanced or recurrent sarcoma of the uterus.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Endometrial Cancer
Sarcoma		 Drug: pegylated liposomal doxorubicin hydrochloride Phase 2

Verified by Gynecologic Oncology Group November, 2005

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00005643

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Gregory P. Sutton, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.